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Gertrude S. Henle (1912–2006)Gertrude S. Henle, internationally acclaimed virologist, died
at age 94 on September 1, 2006, after a long-standing illness.
Dr. Henle and her husband, Werner, discovered in 1966 that the
herpesvirus, Epstein–Barr virus (EBV), caused infectious
mononucleosis, and they later established the association of
EBV with Burkitt's lymphoma and nasopharyngeal carcinoma,
as well as other human clinical conditions. The National Library
of Medicine called the Henles a “prodigious” force in virology,
immunology, and pharmacology during the second half of the
20th century.
Gertrude (Brigitte) Henle received her medical degree in
1936 from the University of Heidelberg, where she met her
husband. Werner emigrated to the United States in 1936 to work
at the University of Pennsylvania. She arrived 1 year later and,
on that day, they were married. Dr. Gertrude Henle also became
a faculty member of the Microbiology Department at the
University of Pennsylvania and began research at Children's
Hospital of Philadelphia in 1941. Medical virology was still in
its infancy but the Henles, undeterred, began work on an
amazingly broad range of pathogenic viruses (e.g., influenza,doi:10.1016/j.virol.2006.11.001mumps, polio, hepatitis A, Newcastle, vesicular stomatitis,
EBV). In the 1940s, they proved the effectiveness of vaccines
for influenza and mumps viruses and showed how infectious
hepatitis virus could be suppressed by gamma globulins. Their
early work on the influenza virus heralded the recognition of
viral interference, although interferon itself had not yet been
discovered. Between the 1950s and 1980s, the Henles pioneered
many of the virologic and serologic techniques utilized in
laboratory diagnosis, several of which are still in use today. The
Henles retired from the University of Pennsylvania in 1982 but
continued their research at Children's Hospital until Werner's
death in 1987.
Brigitte and Werner Henle were the first to discover a virus
associated with human cancer, by showing how an oncogenic
virus such as EBV could transform healthy cells with finite life
spans into malignant ones that can be propagated in vitro
indefinitely. They went on to demonstrate the presence of the
virus in tumor biopsies and correlated the relapse of the
malignancy with increasing tumor burden. They accomplished
these findings on EBV with the simple use of a microscope and
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syndromes. At a time when the field of science was advancing
with several new technologies and breakthroughs in molecular
biology, Brigitte and Werner made their observations using
conventional virologic and immunologic approaches, many of
which they developed. With innovative insight, they demon-
strated how the immune system can reveal the association of a
virus with a particular cancer or clinical condition and how this
information can help physicians determine the severity of a
human disease.
The Henles were married for 50 years at the time of
Werner's death. They worked as an inseparable team and
were complementary in character. Brigitte was outspoken,
energetic, and imaginative and readily took up new
challenges. Werner was quiet, thoughtful, and methodic. Not
infrequently, Brigitte, a prolific reader, would burst into the
laboratory with new ideas, inspired by new reports in
journals. Werner would mull over the possibilities, and then
together they executed systematic experiments to evaluate
their hypotheses. Werner, a prolific writer, would draft the
manuscript, which Brigitte corrected and edited. They jointly
published over 420 publications in major journals dealing
with viral diseases and cancer. Gertrude authored an
additional 25 papers without Werner.
Brigitte often talked about her research life as reflecting
the “blue flower” story. In that tale, a man greatly adored a
blue flower growing along the side of a road but it later
disappeared. He went in search of this flower throughout the
world. After 20 years without success, he returns disap-
pointed to his house, only to find the flower growing
abundantly in his backyard. Brigitte felt her work in science
reflected such serendipitous events that were around her,
waiting to be discovered. I was part of that blue flower
story. In 1964, I was a Columbia University medical student
in Uganda learning about tropical diseases and Burkitt's
lymphoma, a malignancy reported at the time only in
African children. I returned to the United States some
months later with blood specimens collected from patients
and healthy children, in preparation for future investigations
on Burkitt's lymphoma. The Henles were at the time
elucidating the identity of a herpes-like virus described by
Epstein, Barr, and Achong in established Burkitt's lym-
phoma cell lines. They needed blood from Burkitt's
lymphoma patients and controls for these studies. At a
Columbia University conference in 1967, they made
inquiries about a source of suitable specimens and learned
of my 1964 collection. Much to their surprise, my sister,
Ellen, was doing her Ph.D. rotation in their laboratory and I
was doing my internship nearby at the Hospital of the
University of Pennsylvania. The phone call that I received
from Werner established a very warm and fruitful relation-
ship that lasted for over 35 years.
When I brought the human sera to the laboratory for
them, Brigitte responded: “We will teach you how to do the
immunofluorescent testing, and you can do the studies here
in your free time.” That meant evenings and weekends. I
jumped at the chance to work with them. Our studiesshowed a high level of antibodies to EBV in Burkitt's
lymphoma patients but unexpectedly also in healthy young
African children. The Henles correctly surmised that EBV
infection was common, but with rare manifestation as
Burkitt's lymphoma. They taught me then how studies of
survivors of viral infections (such as EBV) provide a great
opportunity to gain insights into the basic pathogenesis of
infectious diseases. That message has served me well in
human immunodeficiency virus (HIV) research.
Another blue flower story involved their young technician,
Elaine Hutkin, who regularly donated blood to be used as the
negative control for experiments attempting to transfer EBV
from Burkitt's lymphoma cell lines to normal B cells. These
studies were probably the first using irradiated human
monolayer cells. Elaine fell ill with infectious mononucleosis.
After her convalescence, she again resumed her blood
donation. To everyone's surprise, her B lymphocytes were
now positively infected with EBV and she had converted to
EBV seropositivity during her illness. Additional tests by the
Henles on more mononucleosis patients quickly confirmed the
causative role of EBV in the disease. I was then at the National
Institutes of Health and received their phone call informing me
of their excitement with this unexpected discovery. What then
ensued were several years in which they showed how EBV
played a role in Burkitt's lymphoma and nasopharyngeal
carcinomas, infectious mononucleosis, and perhaps other
lymphomas.
In an era when air travel was uncommon, the Henles
worked with collaborators all over the world, some from a
distance, but many spent time in their Philadelphia
laboratory. By the early 1970s, their human serum collection
numbered in the tens of thousands and originated from
numerous countries in all five continents. Their collabora-
tions were impressive in breadth and duration, spanning
many decades, such as the one with George Klein, the noted
immunologist at the Karolinska Institute in Sweden.
Together, they contributed greatly to seroepidemiologic
information and diagnostic procedures for EBV infection.
Their differential multiantigen–multiantibody serologic
approach was later adopted for hepatitis B diagnosis and,
more recently, for the Kaposi sarcoma-associated human
herpesvirus and HIV.
Over the years, the Henles played important roles in the
careers of many well-known scientists. Brigitte's imaginative
mind and insightful thinking made her an excellent mentor for
introducing students to potential undiscovered areas. Anyone
who interacted with Brigitte was impressed with her high
energy, her excitement over science, and her eagerness to share
new ideas in long conversations about the search for solutions
to human infectious diseases. Along with Werner, she
combined values of insight, hard work, ethical conduct, and
integrity in the pursuit of answers to the challenges of medical
problems.
In 1979, Gertrude Henle was among the first women
elected to the U.S. National Academy of Sciences. Together
with Werner, she received many awards, including the Mead
Johnson Award for Research in Pediatrics (1950); the Smith,
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the Robert Koch-Medaille (1971); the Robert de Villeirs
Award of the Leukemia Society of America (1975); the
Founders in Cancer Immunology award of the Cancer
Research Institute (1975); the Virus Cancer Program Award
of the National Cancer Institute (1975); the Scientific Award
of the Philadelphia Chapter of the American Cancer Society
(1977); the Bristol-Myers Award for Distinguished Achieve-ment in Cancer Research (1979); and the Children's Hospital
Gold Medal Award (1983).
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